Immunome Inc (IMNM)
14.92
+0.21
(+1.43%)
USD |
NASDAQ |
May 31, 16:00
14.92
0.00 (0.00%)
After-Hours: 20:00
Immunome Enterprise Value: 585.03M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 585.03M |
| May 30, 2024 | 572.44M |
| May 29, 2024 | 567.04M |
| May 28, 2024 | 567.04M |
| May 24, 2024 | 543.05M |
| May 23, 2024 | 550.25M |
| May 22, 2024 | 555.05M |
| May 21, 2024 | 508.87M |
| May 20, 2024 | 517.86M |
| May 17, 2024 | 519.66M |
| May 16, 2024 | 553.85M |
| May 15, 2024 | 577.83M |
| May 14, 2024 | 573.04M |
| May 13, 2024 | 626.41M |
| May 10, 2024 | 619.81M |
| May 09, 2024 | 618.61M |
| May 08, 2024 | 631.81M |
| May 07, 2024 | 609.62M |
| May 06, 2024 | 617.41M |
| May 03, 2024 | 634.40M |
| May 02, 2024 | 587.65M |
| May 01, 2024 | 570.86M |
| April 30, 2024 | 533.10M |
| April 29, 2024 | 518.71M |
| April 26, 2024 | 513.32M |
| Date | Value |
|---|---|
| April 25, 2024 | 545.09M |
| April 24, 2024 | 542.20M |
| April 23, 2024 | 565.48M |
| April 22, 2024 | 602.49M |
| April 19, 2024 | 614.43M |
| April 18, 2024 | 715.92M |
| April 17, 2024 | 727.86M |
| April 16, 2024 | 788.76M |
| April 15, 2024 | 815.62M |
| April 12, 2024 | 918.90M |
| April 11, 2024 | 945.17M |
| April 10, 2024 | 903.97M |
| April 09, 2024 | 912.93M |
| April 08, 2024 | 892.63M |
| April 05, 2024 | 899.80M |
| April 04, 2024 | 899.80M |
| April 03, 2024 | 979.79M |
| April 02, 2024 | 967.26M |
| April 01, 2024 | 1.010B |
| March 31, 2024 | 1.164B |
| March 28, 2024 | 1.331B |
| March 27, 2024 | 1.381B |
| March 26, 2024 | 1.373B |
| March 25, 2024 | 1.282B |
| March 22, 2024 | 1.248B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-15.71M
Minimum
May 13 2022
1.421B
Maximum
Mar 07 2024
184.32M
Average
105.64M
Median
Enterprise Value Benchmarks
| Exelixis Inc | 5.355B |
| Ayala Pharmaceuticals Inc | 14.16M |
| CEL-SCI Corp | 60.22M |
| AIM ImmunoTech Inc | 10.88M |
| IGC Pharma Inc | 29.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -129.49M |
| Revenue (Quarterly) | 1.029M |
| Total Expenses (Quarterly) | 21.37M |
| EPS Diluted (Quarterly) | -12.55 |
| Profit Margin (Quarterly) | -12.58K% |
| Earnings Yield | -104.0% |
| Normalized Earnings Yield | -31.18 |